For the quarter ending 2025-09-30, CGEM made $60,688K in revenue. -$50,610K in net income. Net profit margin of -83.39%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 41,968 | - | ||
| General and administrative | 13,627 | - | ||
| Total operating expenses | 55,595 | - | ||
| Loss from operations | -55,595 | - | ||
| Interest income | 5,093 | - | ||
| Other expense, net | -108 | - | ||
| Net loss | -50,610 | -70,055 | ||
| Unrealized gain (loss) on investments | - | 102 | ||
| Comprehensive loss | - | -69,953 | ||
| Comprehensive loss attributable to noncontrolling interests | - | 0 | ||
| Net loss attributable to noncontrolling interests | 0 | - | ||
| Comprehensive loss attributable to cullinan | - | -69,953 | ||
| Net loss attributable to cullinan | -50,610 | - | ||
| Basic | 59,075,000 | - | ||
| Diluted | 59,075,000 | - | ||
| Net loss per share, basic | -0.77 | - | ||
| Net loss per share, diluted | -0.77 | - | ||
Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics, Inc. (CGEM)